August 24, 2018 09:04 AM EDT
R&D

Zai Lab bombs Phase IIa tri­al in atopic der­mati­tis, junks the pro­gram to shift re­sources to the pipeline

Brittany Meiling

Nas­daq dar­ling and Shang­hai hot­shot Zai Lab is ditch­ing one of its late-stage drug pro­grams af­ter bomb­ing a Phase IIa tri­al. The com­pa­ny said Fri­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times